Adding Duodenal Bypass to Sleeve Gastrectomy Doubles Diabetes Remission While Lowering Insulin Demand | Research

The takeaway

Combining duodenal-jejunal bypass with sleeve gastrectomy achieved 62% complete diabetes remission versus 32% with sleeve gastrectomy alone, with lower C-peptide levels suggesting preserved beta-cell function.

62% vs 32% remission
Complete diabetes remission rates at one year, with the combined surgery nearly doubling remission despite similar weight loss

What the researchers found

At one year post-surgery, the duodenal-jejunal bypass with sleeve gastrectomy (DJB-SG) group achieved 62% complete diabetes remission (HbA1c < 6.0%) compared to 32% in the sleeve gastrectomy (SG) group (P < 0.05), despite similar total body weight loss (25.7% vs. 22%). The DJB-SG group showed significantly lower postprandial blood glucose levels and lower C-peptide levels during mixed-meal tolerance testing, indicating improved glycemic control with reduced beta-cell secretory demand.

No significant differences were found in appetite sensations between groups, suggesting the metabolic benefit of duodenal-jejunal exclusion operates through gut hormone signaling pathways rather than changes in food intake behavior.

Why it matters

This study provides mechanistic evidence that bypassing the duodenum and upper jejunum improves diabetes outcomes through changes in peptide hormone signaling — not just weight loss or reduced eating. The lower C-peptide levels in the DJB-SG group suggest beta-cell preservation, which could mean longer-lasting diabetes remission. This has implications for understanding how gut-derived peptide hormones like GLP-1 and GIP regulate blood sugar.

How the study worked

This retrospective comparative study included 46 type 2 diabetes patients — 21 who underwent DJB-SG and 25 who had SG alone. All patients completed mixed-meal tolerance tests (MMTT) before surgery and at one year, with blood glucose, C-peptide, and insulin measured at multiple time points. Appetite was assessed using visual analogue scales rating six different appetite sensations during the meal test.

What this study cannot tell us

This was a retrospective study with a small sample size of 46 patients, without randomization or blinding. The one-year follow-up may not reflect long-term durability of diabetes remission. The study did not directly measure gut peptide hormones like GLP-1 or GIP, which would have provided stronger mechanistic evidence. Selection bias may exist between the two surgical groups, as patient characteristics differed at baseline.

How to read the evidence

This is a retrospective comparative study without randomization, representing moderate-quality evidence. While the clinical outcomes are compelling, the small sample size, lack of blinding, and potential selection bias limit the strength of causal conclusions. The findings are hypothesis-generating and support further investigation.

When this study was published

Published in 2016, this study is about a decade old. Since then, the understanding of gut peptide hormones in metabolic surgery has advanced significantly, and GLP-1 agonist medications have become mainstream treatments for diabetes and obesity.

The bigger picture

This study fits into a growing body of research showing that metabolic surgery benefits diabetes through mechanisms beyond weight loss — specifically through altered secretion of gut peptide hormones (incretins). The same principles underlie the success of GLP-1 receptor agonist drugs like semaglutide. Understanding how surgical rerouting of food through the gut changes peptide hormone release helps explain both why these surgeries work and why incretin-based peptide drugs are effective for diabetes.

Questions still open

Does the beta-cell preservation suggested by lower C-peptide levels translate into more durable diabetes remission beyond one year?
What specific changes in gut peptide hormones (GLP-1, GIP, PYY) drive the improved glycemic control seen with duodenal-jejunal exclusion?
Could these findings inform the development of peptide-based therapies that mimic the hormonal effects of duodenal bypass without surgery?

Common questions

What is C-peptide and why does it matter in this study?

C-peptide is a short peptide chain released by the pancreas in equal amounts to insulin — it's essentially a byproduct of insulin production. Measuring C-peptide tells researchers how hard the pancreas is working to produce insulin. In this study, lower C-peptide levels in the combined surgery group meant the pancreas needed to produce less insulin to achieve better blood sugar control, suggesting the beta cells were being preserved rather than overworked.

How does bypassing part of the small intestine improve diabetes beyond weight loss?

When food bypasses the duodenum and upper jejunum, it reaches the lower intestine faster, where specialized cells release peptide hormones like GLP-1 that enhance insulin sensitivity and regulate blood sugar. This 'incretin effect' improves diabetes through hormonal signaling changes rather than just calorie restriction. It's the same biological mechanism that GLP-1 peptide medications like semaglutide harness.

Read the original research

Compared to Sleeve Gastrectomy, Duodenal-Jejunal Bypass with Sleeve Gastrectomy Gives Better Glycemic Control in T2DM Patients, with a Lower β-Cell Response and Similar Appetite Sensations: Mixed-Meal Study.

Obesity surgery, 26(12), 2862-2872

View on PubMed ↗

Citation

Zachariah, Pulimuttil James; Chen, Chih-Yen; Lee, Wei-Jei; Chen, Shu-Chu; Ser, Kong-Han; Chen, Jung-Chien; Lee, Yi-Chih. (2016). Compared to Sleeve Gastrectomy, Duodenal-Jejunal Bypass with Sleeve Gastrectomy Gives Better Glycemic Control in T2DM Patients, with a Lower β-Cell Response and Similar Appetite Sensations: Mixed-Meal Study.. Obesity surgery, 26(12), 2862-2872.